Cited 59 times in
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2018-03-26T16:56:50Z | - |
dc.date.available | 2018-03-26T16:56:50Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/156989 | - |
dc.description.abstract | BACKGROUND: The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC). METHODS: ACC patients with documented disease progression within the past 12 months were eligible. Patients received oral dovitinib (500 mg once daily for 5 consecutive days followed by a 2-day rest every week) until disease progression or unacceptable toxicities. The primary endpoint was the probability of 4-month progression-free survival (PFS). Metabolic response was evaluated with positron emission tomography (PET)/computed tomography (CT) scans performed at the baseline and after 8 weeks of treatment. RESULTS: Between September 2011 and April 2013, 32 patients with metastatic and/or unresectable ACC were enrolled in this prospective, multicenter trial. The 4-month PFS probability was 80.4%, and the median PFS was 6.0 months (95% confidence interval, 4.4-7.6 months). Tumor shrinkage was observed in 22 patients (68.8%), and 1 patient had a confirmed partial response. The disease control rate was 96.9%. Among 26 patients with PET/CT scans both before and after treatment (at 8 weeks), the metabolic activity of ACC was reduced in 13 patients (50.0%), and 5 patients (19.2%) achieved a metabolic partial response, which was defined as a ≥25% reduction in maximum standardized uptake values. Common grade 3 and 4 adverse events were asthenia (50.0%) and neutropenia (25.0%). CONCLUSIONS: Dovitinib shows modest antitumor activity in the treatment of ACC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley | - |
dc.relation.isPartOf | CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Benzimidazoles/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Adenoid Cystic/drug therapy* | - |
dc.subject.MESH | Carcinoma, Adenoid Cystic/mortality | - |
dc.subject.MESH | Carcinoma, Adenoid Cystic/pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Head and Neck Neoplasms/drug therapy* | - |
dc.subject.MESH | Head and Neck Neoplasms/mortality | - |
dc.subject.MESH | Head and Neck Neoplasms/pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Quinolones/therapeutic use* | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Salivary Gland Neoplasms/drug therapy | - |
dc.subject.MESH | Salivary Gland Neoplasms/mortality | - |
dc.subject.MESH | Salivary Gland Neoplasms/pathology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Seong Hoon Shin | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Hwan-Jung Yun | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Dok Hyun Yoon | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.identifier.doi | 10.1002/cncr.29401 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J00434 | - |
dc.identifier.eissn | 1097-0142 | - |
dc.identifier.pmid | 25903089 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1002/cncr.29401/abstract | - |
dc.subject.keyword | adenoid cystic carcinoma | - |
dc.subject.keyword | clinical trial | - |
dc.subject.keyword | dovitinib | - |
dc.subject.keyword | dovitinib (TKI258) | - |
dc.subject.keyword | fibroblast growth factor receptor (FGFR) | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.citation.volume | 121 | - |
dc.citation.number | 15 | - |
dc.citation.startPage | 2612 | - |
dc.citation.endPage | 2617 | - |
dc.identifier.bibliographicCitation | CANCER, Vol.121(15) : 2612-2617, 2015 | - |
dc.identifier.rimsid | 41298 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.